How should I taper off Lunesta (eszopiclone) 2 mg?

How to Taper Off Lunesta 2mg

Taper Lunesta 2mg gradually using hyperbolic (proportionate) dose reductions of approximately 5-10% of your current dose every 2-4 weeks, adjusting the pace based on withdrawal symptoms, and be prepared to taper over several months to a year if needed.

Tapering Approach

The most critical principle is to avoid abrupt discontinuation. The FDA label does not provide specific tapering guidance 1, but recent expert consensus strongly supports hyperbolic tapering over linear reductions 2, 3.

Why Hyperbolic Tapering?

The relationship between benzodiazepine receptor agonist (BZRA) dose and brain receptor activity is hyperbolic—not linear. This means:

• Linear reductions (e.g., cutting 0.5mg every 2 weeks) produce increasingly large pharmacological effects as you approach zero, causing escalating withdrawal symptoms 3
• Hyperbolic reductions (e.g., 10% of current dose) produce consistent pharmacological changes, minimizing withdrawal risk 2, 3

Specific Tapering Protocol

Starting from 2mg:

• Reduce by 10% of current dose every 2-4 weeks
• Example schedule: 2mg → 1.8mg → 1.6mg → 1.45mg → 1.3mg, continuing down
• At very low doses (below 0.5mg), you may need reductions as small as 0.05-0.1mg 3
• Final doses may need to be as low as 0.2mg or less before stopping completely 3

Pace adjustment:

• If withdrawal symptoms emerge, pause the taper or return to the previous dose 2
• Some patients require tapering over 6-12 months or longer 2, 3
• Monitor every 2-4 weeks during active tapering

Practical Considerations

Obtaining Small Doses

Since Lunesta tablets cannot be split accurately for very small reductions:

• Request compounded formulations from specialty pharmacies 2
• Consider liquid preparations for precise dosing at low doses 3
• Novel preparation techniques may be necessary 2

Risk Factors for Difficult Discontinuation

You're at higher risk for withdrawal if you have:

• Hyperarousal (heightened physiological arousal) 4
• Poor medication compliance patterns during treatment 5
• Longer duration of use (>6 months) 5
• History of dependence behaviors 5

Notably, eszopiclone (Lunesta) users had more difficulty discontinuing than zolpidem users in controlled studies 4, suggesting you should be particularly cautious.

Withdrawal Symptoms vs. Insomnia Relapse

Critical distinction: Withdrawal symptoms can mimic insomnia but are pharmacologically distinct:

• Withdrawal symptoms typically emerge within 1-3 days of dose reduction
• They may include anxiety, restlessness, perceptual disturbances, and rebound insomnia
• About 10.5% of patients experience clinically significant withdrawal (BHWSS score ≥7) after 24 weeks of use 5
• Importantly, post-discontinuation insomnia severity was not significantly different between those with and without withdrawal symptoms 5

If symptoms emerge, this likely represents withdrawal rather than return of original insomnia—slow or reverse the taper rather than resuming full dose.

Supportive Measures

Strong consensus recommendations 2:

• Obtain informed consent before starting the taper—discuss realistic timelines and potential challenges
• Use shared decision-making throughout—you control the pace
• Consider psychosocial interventions (CBT-I, sleep hygiene counseling)
• Utilize peer support resources for people discontinuing hypnotics

Moderate/weak consensus:

• Avoid adding other medications to manage withdrawal 2
• Converting to a longer-acting benzodiazepine (like diazepam) received only moderate support and is not necessary for most 2

Common Pitfalls to Avoid

1. Tapering too quickly: The most common error. If you experience significant discomfort, you're reducing too fast
2. Using linear reductions: Cutting the same amount each time (e.g., 0.5mg every 2 weeks) will become increasingly difficult
3. Stopping at 0.5mg or 1mg: The final reductions are proportionally the largest—continue tapering to very low doses
4. Confusing withdrawal with relapse: Temporary sleep disruption during tapering doesn't necessarily mean your insomnia has returned

Timeline Expectations

• Minimum duration: 2-3 months for uncomplicated tapers
• Typical duration: 6-12 months for most patients
• Extended duration: Up to 2 years may be necessary for some, particularly those with prior failed attempts 2, 3

The American Academy of Sleep Medicine guidelines support eszopiclone use for insomnia 6 but provide no discontinuation guidance, highlighting the gap in official recommendations. The FDA label similarly lacks specific tapering instructions 1. Therefore, this hyperbolic tapering approach based on recent expert consensus 2, 3 and pharmacological principles represents the current best practice for minimizing withdrawal while successfully discontinuing.